经皮冠状动脉介入治疗术后抗血小板治疗依从性调查分析  

Compliance of Antiplatelet Therapies after Percutaneous Coronary Intervention

作　　者：王秀珠[1] 范国峰[2] 

机构地区：[1]东南大学医院药剂科,江苏省南京市210018 [2]南京大学医学院附属鼓楼医院

出　　处：《中国全科医学》2010年第31期3570-3571,共2页Chinese General Practice

摘　　要：目的分析经皮冠状动脉介入治疗(PCI)术后抗血小板治疗依从性的现状、影响因素和对策。方法采用回顾性方法,调查和分析患者接受PCI后抗血小板治疗的用药情况及其影响因素。结果 187例PCI术后患者,双重抗血小板依从性好的在术后3个月占89.9%,术后1年降至82.3%。药品副作用、患者的用药知识、对冠心病的了解及医师指导等因素是影响患者用药依从性的主要因素。结论 PCI术后抗血小板药物治疗依从性不理想,药师和医师应共同肩负起提高术后二级预防用药依从性的重任。Objective To investigate the current status of the compliance of antiplatelet therapies after percutaneous coronary intervention,its influencing factors and the countermeasures.Methods The compliance and its influencing factors of antiplatelet therapies were investigated and analyzed retrospectively in patients who received the percutaneous coronary intervention.Results Among all the 187 patients who received the percutaneous coronary intervention,the rate of adherence to dual antiplatelet therapy was 89.9% at the third month after the intervention,but significantly declined to 82.3% one year later.The main influencing factors of the compliance were adverse drug reactions,patients＇knowledge on medication and about coronary heart disease,and guidance from physicians.Conclusion The compliance of antiplatelet therapies is poor in patients receiving percutaneous coronary intervention.It is the responsibility of both pharmacists and physicians to improve the compliance in the secondary prevention after percutaneous coronary intervention.

关 键 词：经皮冠状动脉介入治疗 氯吡格雷 阿司匹林 依从性 

分 类 号：R541.4[医药卫生—心血管疾病] R969.3[医药卫生—内科学]